Macrod1 suppresses diabetic cardiomyopathy via regulating PARP1-NAD < sup > + < /sup > -SIRT3 pathway

This study identifies Macrod1 as a novel target for DCM treatment. Targeting the PARP1-NAD+-SIRT3 axis may open a novel avenue to development of new intervention strategies in DCM. Schematic illustration of macrod1 ameliorating diabetic cardiomyopathy oxidative stress via PARP1-NAD+-SIRT3 axis.PMID:38459256 | DOI:10.1038/s41401-024-01247-2

Source: Acta Pharmacologica Sinica - March 8, 2024 Category: Drugs & Pharmacology Authors: Yu-Ting Liu Hong-Liang Qiu Hong-Xia Xia Yi-Zhou Feng Jiang-Yang Deng Yuan Yuan Da Ke Heng Zhou Yan Che Qi-Zhu Tang Source Type: research